The effects of dorzolamide nanoliposome in open angle glaucoma

The effects of dorzolamide nanoliposomes in comparison with marketed dosage form on intraocular pressure in open angle glaucoma patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016020426360N1

Enrollment

Registered

2016-05-02

Start date

2016-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open-angle glaucoma. primary open-angle glaucoma

Interventions

Intervention 1: Intervention group 1: dorzolamide nanoliposome 2%.one drop 3 times daily for 2 months. Intervention 2: Intervention group 2: Dorzolamide marketed solution 2%.one drop 3 times daily f

Treatment - Drugs

Intervention group 1: dorzolamide nanoliposome 2%.one drop 3 times daily for 2 months

Intervention group 2: Dorzolamide marketed solution 2%.one drop 3 times daily for 2 months

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients must use only one drug to reduce their intraocular pressure. Exclusion criteria: patients that have hypertension, diabetes , autoimune disease or chronic disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Intraocular pressure. Timepoint: before intervention, in middle(Day 14th and Day 28th) and in long term(Day 42th and Day 56th). Method of measurement: Goldmann applanation tonometry.	—

Secondary

Measure	Time frame
Adverse effects. Timepoint: Days 14? 28? 42 and 56. Method of measurement: patient complaint.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLaleh Andishmand

Ahvaz Jundishapur University of Medical Sciences

andishmand.l@ajums.ac.ir+98 61 3374 1298

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026